Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients
This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
First received: August 26, 2005
Last updated: November 1, 2011
Last verified: November 2011
This study will test the safety and efficacy of everolimus on heart transplant recipients.
This study is not recruiting in the United States.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||A 12-month, Multicenter, Randomized, Open-label Non-inferiority Study of Renal Function and Efficacy Comparing Concentration-controlled Certican (1.5 mg/Day Starting Dose) With Reduced Neoral Dose Versus MMF With Standard Neoral Dose in de Novo Heart Transplant Recipients|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Novartis:
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00150046
|Novartis Investigational Site|
|Basel Novartis Pharma AG|
Sponsors and Collaborators
|Study Chair:||Basel Novartis Pharma AG||Basel Novartis Pharma AG|